Tocagen Inc. (Nasdaq: TOCA) licensed its Phase III stage candidate Toca 511 & Toca FC to ApolloBio (NEEQ: 430187). The deal includes an upfront payment of $16 million, a near-term $4 million milestone after clinical trials and other additional future payments totaling up to $107 million. The deal is worth of $127 million in total. According to the deal terms, ApolloBio will gain exclusive rights of Toca 511 & Toca FC and will be responsible for developing and commercializing the candidate in Greater China, including mainland China, Hong Kong, Macao and Taiwan.
Source: Biospace
